Literature DB >> 3532293

Cimetidine, 800 mg once daily: preliminary European clinical data evaluation.

B Dickson.   

Abstract

A multicenter study was carried out on a total of 574 patients to investigate the safety and efficacy of a 800-mg nighttime dose of cimetidine in comparison with 400 mg twice daily for 4 or 8 weeks in the treatment of patients with duodenal ulcer. No statistically significant differences were observed between the two regimens. Healing rates were as follows: at 4 weeks 212 of 269 patients (79%) healed with the once daily regimen whereas 200 of 270 patients (74%) healed with the twice daily dosage; at 8 weeks 242 of 251 patients (96%) healed with the once daily regimen as compared with 232 of 246 (94%) treated with the twice daily dosage. The dosages were equally effective in relief of pain during the study period. The results confirm that a single nighttime dose of cimetidine is as effective as the twice daily regimen.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3532293     DOI: 10.3109/00365528609091672

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  4 in total

Review 1.  Formulary management of antiulcer drugs: clinical considerations.

Authors:  S L Sankey; L S Friedman
Journal:  Pharmacoeconomics       Date:  1994-03       Impact factor: 4.981

Review 2.  Optimal reduction of gastric acid secretion in the treatment of peptic ulceration.

Authors:  H G Dammann; M Dreyer; R Kangah; P Müller; B Simon
Journal:  Drugs       Date:  1988       Impact factor: 9.546

3.  Low bedtime doses of H2-receptor antagonists for acute treatment of duodenal ulcer.

Authors:  V Savarino; G S Mela; P Zentilin; G Bonifacino; M Moretti; F Valle; G Celle
Journal:  Dig Dis Sci       Date:  1989-07       Impact factor: 3.199

Review 4.  Histamine H2-receptor antagonists in peptic ulcer disease. Efficacy in healing peptic ulcers.

Authors:  M Deakin; J G Williams
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.